Early and effective detection of addictive and hallucinogen potential in the next generation of psychoactive drugs to speed up the implementation of control measures by the EU.

Funded by the European Union

Current project progress:



At the end of 2019, the EMCDDA had identified more than 700 new psychoactive substances (NPS). Among them, there are the new psychostimulants and hallucinogens, which are used as drugs of abuse, but their short/long-term adverse effects are unknown. These NPS are designed to mimic traditional drugs...


By the end of 2019, the EMCDDA monitored around 790 NPS and every year more than 50 NPS are being detected for the first time by the EU-Early Warning System. They emerged due to their availability, price and psychoactive potency. Many of them are designed to mimic existing scheduled drugs and used as an alternative to MDMA, amphetamines, cocaine and LSD. However, the knowledge about...


To early identify and characterize those new synthetic psychostimulants and hallucinogens with high abuse liability and/or psychedelic effects.

To select eight NPS

(3 cathinone-, 2 phenethylamine- and 3 tryptamine-derivatives)...

To synthesize

and characterize the selected NPS...

To design

an analytical protocol allowing the detection in biological samples and seized materials…

To characterize

the mechanism of action of the selected NPS…

To study

the psychostimulant and reinforcing effects of selected cathinones and phenethylamines…

To study

the abuse potential of the selected cathinones and phenethylamines…

To study

the hallucinogen properties of phenethylamines and tryptamine derivatives…





Technical Reports


Posters and presentations



latest news

News & Articles

No Content Available
More news at:
No Content Available

Contact Info


Getting an accurate diagnosis can be one of the most impactful experiences that you can have.

Copyright © 2022 NextGenPS. All Rights Reserved | Web design by beta!ent